GH Research PLC 正积极与美国食品药品监督管理局（FDA）进行沟通，旨在就其计划中的全球三期关键性临床试验项目达成共识。公司方面表示，尽管正在进行相关讨论，其目标启动时间窗口依然设定在2026年晚些时候。这一全球性关键项目对于公司核心候选药物的最终审批至关重要。
GH Research PLC 正积极与美国食品药品监督管理局（FDA）进行沟通，旨在就其计划中的全球三期关键性临床试验项目达成共识。公司方面表示，尽管正在进行相关讨论，其目标启动时间窗口依然设定在2026年晚些时候。这一全球性关键项目对于公司核心候选药物的最终审批至关重要。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.